Search

Your search keyword '"Levinte, Doina"' showing total 5 results
Start Over Author "Levinte, Doina"
5 results on '"Levinte, Doina"'

1. Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

Author

Yong, Kwee, primary, Royle, Kara-Louise, additional, Ramasamy, Karthik, additional, Parrish, Christopher, additional, Hockaday, Anna, additional, Asher, Samir, additional, Drayson, Mark T, additional, de Tute, Ruth M., additional, Jenner, Matthew W, additional, Kaiser, Martin F., additional, Pratt, Guy, additional, Sive, Jonathan, additional, Bygrave, Ceri, additional, Cook, Gordon, additional, Popat, Rakesh, additional, Smith, Dean, additional, Olivier, Catherine, additional, Barnard, Lorna, additional, Levinte, Doina, additional, Dawkins, Bryony, additional, Chapman, Michael A, additional, Chantry, Andrew D, additional, Jackson, Graham, additional, Quezada, Sergio A, additional, Owen, Roger G, additional, and Cairns, David, additional

Published
2022
Full Text
View/download PDF

2. P-206: Antibodies to omicron variants are maintained in newly diagnosed MM patients on lenalidomide, cyclophosphamide, bortezomib and dexamethasone (RCyBorD): results from the UK RADAR/Myeloma XV Trial

Author

Asher, Samir, primary, Faustini, Sian, additional, paterson, Andrea, additional, Royle, Kara-Louise, additional, Coulson, Amy, additional, Barnard, Lorna, additional, Liaquat, Aleena, additional, Levinte, Doina, additional, Hockaday, Anna, additional, Olivier, Catherine, additional, Cairns, David, additional, Parrish, Christopher, additional, Cook, Gordon, additional, Jackson, Graham, additional, Chapman, Michael, additional, Kaiser, Martin, additional, Jenner, Matthew, additional, Bygrave, Ceri, additional, Sive, Jonathan, additional, Popat, Rakesh, additional, Pratt, Guy, additional, Richter, Alex, additional, Drayson, Mark, additional, Ramasamy, Karthik, additional, and Yong, Kwee, additional

Published
2022
Full Text
View/download PDF

3. High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Author

Mehta, Dipal, Chiecchio, Laura, Kaiser, Martin F., Gooding, Sarah, Royle, Kara-Louise, Levinte, Doina, Olivier, Catherine, Cairns, David Allan, Barnard, Lorna, Jackson, Sharon, Cicero, Robert, Cook, Gordon, Chapman, Michael A., Chant, Alan, Meads, David, Dawkins, Bryony, Pratt, Guy, Popat, Rakesh, Jackson, Graham, Bygrave, Ceri, Chantry, Andrew, Sive, Jonathan, Parrish, Christopher, Smith, Dean, Drayson, Mark, Owen, Roger, de Tute, Ruth M, Ramasamy, Karthik, Yong, Kwee, and Jenner, Matthew W.

Published
2023
Full Text
View/download PDF

4. Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)

Author

Lecat, Catherine SY, Chant, Alan, McCourt, Orla, Meads, David, Cicero, Robert, Royle, Kara-Louise, Bygrave, Ceri, Chantry, Andrew, Chapman, Michael A., Cook, Gordon, Dawkins, Bryony, Drayson, Mark, Jackson, Graham, Jenner, Matthew W., Kaiser, Martin F., Mehta, Dipal, Owen, Roger, Popat, Rakesh, Parrish, Christopher, Pratt, Guy, Sive, Jonathan, Smith, Dean, de Tute, Ruth M, Barnard, Lorna, Jackson, Sharon, Levinte, Doina, Olivier, Catherine, Ramasamy, Karthik, Yong, Kwee, and Cairns, David Allan

Abstract

Introduction

Published
2023
Full Text
View/download PDF

5. RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients

Author

Ramasamy, Karthik, Cairns, David Allan, Royle, Kara-Louise, Cicero, Robert, Olivier, Catherine, Barnard, Lorna, Jackson, Sharon, Levinte, Doina, Cook, Gordon, Chant, Alan, Meads, David, Dawkins, Bryony, Chapman, Michael A., Pratt, Guy, Popat, Rakesh, Jackson, Graham, Bygrave, Ceri, Chantry, Andrew, Kaiser, Martin F., Sive, Jonathan, Parrish, Christopher, Smith, Dean, Jenner, Matthew W., Drayson, Mark, Owen, Roger, de Tute, Ruth M, Mehta, Dipal, and Yong, Kwee

Abstract

Background: Achieving and sustaining minimal disease negativity improves clinical outcomes in newly diagnosed transplant eligible myeloma (NDMM). Outcomes in NDMM are influenced by levels of minimal residual disease (MRD) post therapy and genetic risk by FISH or molecular profiling prior to therapy. Trials exploring response adapted post transplant strategies using MRD as a prognostic tool are going. We provide an update of the current UK-MRA RADAR study.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results